Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

910
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
910
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

869
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
869
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

5.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

250
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
250

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Molecular Drivers of Contrasting Photoreactivity in Extracellular versus Intracellular Organic Matter from Chlorophyta and Cyanobacteria.

Environmental science & technology·2026
Same author

Correction: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes.

Cancer cell international·2026
Same author

Effects of Bicarbonate Ions in Tea Brewing Water on Sensory Properties and Substances of Different Teas.

Foods (Basel, Switzerland)·2026
Same author

Wastewater treatment process optimization in stochastic game based on multiagent deep reinforcement learning.

Water research·2026
Same author

Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma.

NPJ precision oncology·2026
Same author

Prognostic value of chemotherapy-related mean corpuscular hemoglobin (MCH) kinetics in patients with non-small cell lung cancer receiving adjuvant chemotherapy.

Cancer treatment and research communications·2026

Video Experimental Relacionado

Updated: Sep 9, 2025

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.0K

Eficacia comparativa de los inhibidores de la enzima de conversión de la angiotensina frente a los bloqueadores de

Chao Xie1,2, Ruixuan Chen1, Shiyu Zhou1

  • 1Division of Nephrology, Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease; State Key Laboratory of Organ Failure Research; Guangdong Provincial Institute of Nephrology; Guangdong Provincial Key Laboratory of Renal Failure Research, China (C.X., R.C., S.Z., Y.L., J.L., L.S., M.P., Z.G., F.L., S.N.).

Hypertension (Dallas, Tex. : 1979)
|September 4, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Los inhibidores de la enzima de conversión de la angiotensina (ECA) se relacionaron con un mayor riesgo de muerte y eventos cardiovasculares adversos mayores en comparación con los bloqueadores de los receptores de la angiotensina (ARB). Esto sugiere que la selección cuidadosa de estos medicamentos vitales de protección cardiovascular y renal es crucial.

Palabras clave:
Biobanco del Reino UnidoInhibidores de la enzima de conversión de la angiotensinaEnfermedades cardiovasculareslos humanosIncidencia de la enfermedad

Más Videos Relacionados

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

653

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.0K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

653

Área de la Ciencia:

  • Medicina cardiovascular
  • Farmacología
  • Nefrología

Sus antecedentes:

  • Los inhibidores de la enzima de conversión de la angiotensina (ECA) y los bloqueadores de los receptores de la angiotensina (ARB) se recomiendan para la protección cardiovascular y renal.
  • La eficacia comparativa a largo plazo de los inhibidores de la ECA frente a los ARB en la mortalidad no está bien establecida.

Objetivo del estudio:

  • Comparar la eficacia a largo plazo de la administración de inhibidores de la ECA frente a los ARB en la mortalidad por cualquier causa y en los eventos cardiovasculares adversos importantes.
  • Proporcionar pruebas para una selección óptima de inhibidores del sistema de angiotensina-aldosterona.

Principales métodos:

  • Estudio de cohorte de base de datos múltiple utilizando el Biobanco del Reino Unido y el Sistema de datos renales de China.
  • Marco de emulación del ensayo objetivo con puntuación de propensión para nuevos usuarios de inhibidores de la ECA o ARB.
  • Resultado primario: mortalidad por cualquier causa a los 5 años; resultado secundario: eventos cardiovasculares adversos importantes.

Principales resultados:

  • El inicio del tratamiento con inhibidores de la ECA se asoció con un mayor riesgo de mortalidad por cualquier causa a los 5 años (Biobanco del Reino Unido: HR 1. 13; Sistema de datos renales de China: HR 1. 12).
  • Los pacientes que iniciaron el tratamiento con inhibidores de la ECA mostraron un mayor riesgo de eventos cardiovasculares adversos mayores en comparación con los iniciadores de ARB en ambas bases de datos.
  • Los hallazgos consistentes en ambas bases de datos a gran escala refuerzan las conclusiones del estudio.

Conclusiones:

  • El inicio de los inhibidores de la ECA demostró mayores riesgos de mortalidad por cualquier causa y eventos cardiovasculares adversos mayores en comparación con los ARB.
  • Los hallazgos hacen hincapié en la necesidad de una cuidadosa consideración al seleccionar entre inhibidores de la ECA y ARB para el cuidado del paciente.
  • Esta investigación aporta información valiosa sobre la seguridad y eficacia comparativas de estas clases de fármacos ampliamente utilizados.